Table of Content


COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
AstraZeneca Plc - Key Company Facts 9
AstraZeneca Plc - Company Description 10
AstraZeneca Plc - Top Executives 11
AstraZeneca Plc- Top Executives Biographies 12
AstraZeneca Plc- Head Office & Locations 17
Head Office - Country 17
Key Subsidiaries 18
Key Joint Ventures 20
AstraZeneca Plc - Products and Services 21
Products 21
AstraZeneca Plc - Historic Events 23
AstraZeneca Plc – Company’s Management Discussion 25
AstraZeneca Plc – Company’s Mission and Vision 27
Mission 27
Vision 27
AstraZeneca Plc - Corporate Strategy 28
AstraZeneca Plc - Business Description 32
Respiratory & Immunology 32
Cardiovascular, Renal & Metabolism 33
Vaccines & Immune Therapies 35
AstraZeneca Plc - ESG Spotlight 36
Environment 37
Social 37
Corporate Governance 37
AstraZeneca Plc - SWOT Analysis 39
Overview 39
Strengths 41
Weaknesses 45
Opportunities 46
Threats 48
AstraZeneca Plc – PESTLE Analysis 50
Overview 50
Political Factors 52
Economic Factors 55
Social Factors 57
Technological Factors 59
Legal Factors 61
Environmental Factors 63
AstraZeneca Plc - Financial Deep Dive 64
Share Price Trend - Oct-2023to Oct-2024 (Average Share Closing Price) 64
Profit and Loss Statement 66
Summary of Profit and Loss Statement 66
Balance Sheet 68
Summary of Balance Sheet 68
Cash Flow Statement 70
Summary of Cash Flow Statement 70
Key Financial Ratio Analysis 72
AstraZeneca Plc - Ratio Charts 73
Activity Ratio Charts 73
Growth Ratios Charts 74
Leverage Ratio Charts 75
Liquidity Ratio Charts 75
Profitability Ratio Charts 77
Competing Players 78
Snapshot of Competing Players 79
Bayer Aktiengesellschaft (Bayer AG) 79
Key Company Facts 79
Company Description 79
Snapshot of Competing Players 81
Roche Holding AG 81
Key Company Facts 81
Company Description 81
Snapshot of Competing Players 83
GSK plc 83
Key Company Facts 83
Company Description 83
Snapshot of Competing Players 85
Novartis AG 85
Key Company Facts 85
Company Description 85
Snapshot of Competing Players 87
Sanofi SA 87
Key Company Facts 87
Company Description 87
AstraZeneca Plc - In the News 89
16-Oct-2024- AstraZeneca advances science of infectious disease protection at IDWeek 2024 89
14-Oct-2024- Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic non-small cell lung cancer 91
10-Oct-2024- Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care 93
07-Oct-2024- AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy 95
07-Oct-2024- Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial 96
03-Oct-2024- Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma 98
01-Oct-2024- Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy 100
26-Sep-2024- Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer 102
23-Sep-2024- Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis 104
23-Sep-2024- Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial 107
20-Sep-2024- FluMist approved for self-administration in the US 111
18-Sep-2024- Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis 113
16-Sep-2024- Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial 116
11-Sep-2023- TAGRISSO? (osimertinib) plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial 121
25-Aug-2023- AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients 123
27-Jul-2023- ENHERTU? (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial 125
05-Jun-2023- Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial 127
03-Jun-2023- LYNPARZA? (olaparib) and IMFINZI? (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial 129
23-May-2023- New AstraZeneca data presented at ATS 2023 strengthen the body of evidence supporting early intervention with BREZTRI in COPD 131
09-May-2023- FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients 132
05-Apr-2023- LYNPARZA? and IMFINZI? combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumor BRCA mutations in DUO-O Phase III trial 133
02-Mar-2023- Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023 135
23-Jan-2023- AstraZeneca begins tender offer to acquire CinCor Pharma, Inc. 137
AstraZeneca Plc- Key Deals 139
09-Jun-2023 - AstraZeneca signs $2 billion agreement with Quell to develop cell therapies 139
24-Feb-2023 - Acquisition of CinCor Pharma complete 140
16-Jan-2023 - Acquisition of Neogene Therapeutics completed 140
16-Nov-2022 - Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio? Therapeutics 141
11-Aug-2022 - Acquisition of TeneoTwo for its clinical-stage T-cell engager completed 142
21-Jul-2021 - Acquisition of Alexion completed 142
17-Dec-2015 - AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma 144
17-Jul-2013 - AstraZeneca LP completed the acquisition of Omthera Pharmaceuticals, Inc. from Sofinnova Partners, Sofinnova Capital VI, FCPR, New Enterprise Associates and others. 146
Appendix 148
Definitions 148
SWOT Analysis 148
PESTLE Analysis 148
Value Chain Analysis 148
ESG Spotlight 148
Financial Deep Dive 148
Financial Ratios - 149
Activity Ratios 149
Growth Ratios 150
Leverage Ratios 151
Liquidity Ratios 152
Market Ratios 153
Profitability Ratios 153
Research Methodology 154
Disclaimer 155
Contact Us 155



List of Figures

Charts
Figure 1: AstraZeneca Plc- SWOT Analysis 40
Figure 2: AstraZeneca Plc - PESTLE Analysis 51
Figure 3: AstraZeneca Plc - Average Share Price Trend - Oct-2023 to Oct-2024 65
Figure 4: AstraZeneca Plc - Profit and Loss Statement - 2020-2023 67
Figure 5: AstraZeneca Plc - Balance Sheet - 2020-2023 69
Figure 6: AstraZeneca Plc - Cash Flow Statement 2020-2023 71
Figure 7: AstraZeneca Plc - Activity Ratio Charts 73
Figure 8: AstraZeneca Plc - Growth Ratio Charts (Value %) 74
Figure 9: AstraZeneca Plc - Leverage Ratio Charts 75
Figure 10: AstraZeneca Plc - Liquidity Ratio Charts 76
Figure 11: AstraZeneca Plc - Profitability Ratio Charts (Value %) 77
Figure 12: Competing Players - Bayer Aktiengesellschaft (Bayer AG) - Key Financials 80
Figure 13: Competing Players - Roche Holding AG - Key Financials 82
Figure 14: Competing Players - GSK plc - Key Financials 84
Figure 15: Competing Players - Novartis AG - Key Financials 86
Figure 16: Competing Players - Sanofi SA - Key Financials 88

List of Tables

Tables
Table 1: AstraZeneca Plc - Company Facts
Table 2: AstraZeneca Plc - Top Executives
Table 3: AstraZeneca Plc - Top Executives Biographies
Table 4: AstraZeneca Plc - Subsidiaries
Table 5: AstraZeneca Plc - Key Joint Ventures
Table 6: AstraZeneca Plc - Products
Table 7: AstraZeneca Plc - Historic Events
Table 8: AstraZeneca Plc - Share Price Trend - Oct-2023 to Oct-2024
Table 9: AstraZeneca Plc- Ratio Analysis - 2020-2023
Table 10: AstraZeneca Plc -Competing Players